Search - tctmd.com

Displaying 241 - 260 of 308

Sort: Relevancy | Date

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Merck Calls Quits on CETP Inhibitor Anacetrapib

Michael O'Riordan

October 12, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

Todd Neale

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Presentation CHIP Seattle 2017

Inotropes and Drug Therapies for Shock: Data and Outcomes

Presenter: Sunil V. Rao

August 11, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News Daily News

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

Todd Neale

June 27, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

Advertisement

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Merck Calls Quits on CETP Inhibitor Anacetrapib

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

TCTMD’s Top 10 Most Popular Stories for August 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Dual Antithrombotic Approach in Patients With A-fib Undergoing PCI Boosted in RE-DUAL PCI

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Inotropes and Drug Therapies for Shock: Data and Outcomes

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Top-Line REVEAL Results Support Efficacy of CETP Inhibition, but Questions Abound

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content